Michael D Walsh
Overview
Explore the profile of Michael D Walsh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
2446
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Walker R, Mahmood K, Joo J, Clendenning M, Georgeson P, Como J, et al.
J Transl Med
. 2023 Apr;
21(1):282.
PMID: 37101184
Routine screening of tumors for DNA mismatch repair (MMR) deficiency (dMMR) in colorectal (CRC), endometrial (EC) and sebaceous skin (SST) tumors leads to a significant proportion of unresolved cases classified...
2.
Walker R, Mahmood K, Joo J, Clendenning M, Georgeson P, Como J, et al.
medRxiv
. 2023 Mar;
PMID: 36909643
Routine screening of tumors for DNA mismatch repair (MMR) deficiency (dMMR) in colorectal (CRC), endometrial (EC) and sebaceous skin (SST) tumors leads to a significant proportion of unresolved cases classified...
3.
Walker R, Georgeson P, Mahmood K, Joo J, Makalic E, Clendenning M, et al.
J Mol Diagn
. 2022 Nov;
25(2):94-109.
PMID: 36396080
Identifying tumor DNA mismatch repair deficiency (dMMR) is important for precision medicine. Tumor features, individually and in combination, derived from whole-exome sequenced (WES) colorectal cancers (CRCs) and panel-sequenced CRCs, endometrial...
4.
Walsh M
J Res Natl Inst Stand Technol
. 2021 Aug;
121:389-400.
PMID: 34434629
In 2009 and 2010, NIST's Construction Grant Program (NCGP) issued grants to 15 universities and 1 nonprofit institution to construct new or expand existing research facilities. Using $180 million provided...
5.
Vojtek M, Walsh M, Papadimos D, Shield P
Cytopathology
. 2019 Aug;
30(6):614-619.
PMID: 31390089
Objective: To evaluate the utility of claudin-4 as a pan-carcinoma marker in cell-blocks of effusion specimens and compare results with Ber-Ep4 staining. Methods: Effusion cell-blocks (n = 284) were stained...
6.
Georgeson P, Walsh M, Clendenning M, Daneshvar S, Pope B, Mahmood K, et al.
Mol Genet Genomic Med
. 2019 Jun;
7(7):e00781.
PMID: 31162827
Background: Muir-Torre syndrome is defined by the development of sebaceous skin lesions in individuals who carry a germline mismatch repair (MMR) gene mutation. Loss of expression of MMR proteins is...
7.
Walsh M, Jayasekara H, Huang A, Winship I, Buchanan D
Australas J Dermatol
. 2018 Dec;
60(2):126-133.
PMID: 30506759
Background/objectives: Loss of expression of mismatch repair (MMR) proteins is frequently observed in sebaceous skin lesions and can be a herald for Lynch syndrome. The aim of this study was...
8.
Shield P, Crouch S, Papadimos D, Walsh M
J Cytol
. 2018 Apr;
35(2):90-93.
PMID: 29643655
Aims: The utility of GATA3 immunohistochemistry (IHC) as an aid to the cytological diagnosis of metastatic breast carcinoma in fine needle aspiration (FNA) specimens was investigated. Materials And Methods: Cell...
9.
Buchanan D, Clendenning M, Rosty C, Eriksen S, Walsh M, Walters R, et al.
J Gastroenterol Hepatol
. 2016 Jun;
32(2):427-438.
PMID: 27273229
Background And Aim: Tumor testing of colorectal cancers (CRC) for mismatch repair (MMR) deficiency is an effective approach to identify carriers of germline MMR gene mutation (Lynch syndrome). The aim...
10.
Rosty C, Clendenning M, Walsh M, Eriksen S, Southey M, Winship I, et al.
BMJ Open
. 2016 Feb;
6(2):e010293.
PMID: 26895986
Objectives: Immunohistochemistry for DNA mismatch repair proteins is used to screen for Lynch syndrome in individuals with colorectal carcinoma (CRC). Although solitary loss of PMS2 expression is indicative of carrying...